ekso sko17 moving as one - content.equisolve.netoverview_jan+2018+u… · fes interface for...

Ekso BionicsJanuary 2018

#MOVINGASONE© 2018 Ekso Bionics Holdings, Inc. All Rights Reserved.

eksobionics.com

http://www.eksobionics.com/

Ekso Bionics | 2

Forward Looking Statements

© 2018 Ekso Bionics Holdings, Inc. All Rights Reserved.

Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements.

Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for

future operations, including plans or objectives relating to the design, development and commercialization of human

exoskeletons, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial

items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described

in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance,

events or circumstances and may not be realized because they are based upon the Company's current projections, plans,

objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other

influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances

may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors

that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially

from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the

Company's operations and necessary to develop or enhance our technology, the significant length of time and resources

associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the

Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse

results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for

the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of

product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans

or strategies. These and other factors are identified and described in more detail in the Company's public filings with the

Securities and Exchange Commission ("SEC”). You should carefully read our Cautionary Note Regarding Forward-Looking

Statements and the factors described in the "Risk Factors" section of the prospectus filed with the SEC to better understand the

risks and uncertainties inherent in our business. The Company does not undertake to update these forward-looking statements.

Ekso Bionics | 3© 2018 Ekso Bionics Holdings, Inc. All Rights Reserved.

Investment Highlights

Transformative

Technology

Compelling

Medical

Evidence

Robust

Clinical

Evidence

Growing

Commercial

Success

Industrial

Market

Proprietary wearable exoskeletons

Only exoskeleton specifically cleared by FDA for both Stroke and Spinal Cord Injury (SCI)

Multiple large current market opportunities in healthcare

o Stroke: 15 million incidences per year worldwide

o SCI: up to 500,000 incidences per year worldwide

Clinical studies showing improved patient outcomes

o Successfully improving step count and functional independence measures (FIM)

o Industry-first study to evaluate clinical and economic impact of Ekso with SCI patients

$21 billion workplace related injuries on construction sites in the US can be addressed by Ekso’s

proprietary solutions

Over 275 Ekso GT units and 325 EksoWorks products placed in the field

Preliminary Q4 2017 Revenues of $2.5M, up from $1.6M in Q3 2017


Multiple Global Market Opportunities

Unique Opportunity to Address Challenges & Cost of Care in a Large Patient Population

World North America EMEA

Burden of stroke is projected to

grow from ~38M disability-

adjusted life years globally in

1990 to ~61M in 2020.1

15M people worldwide suffer a

stroke.1

Str

oke

SC

I

In Europe, stroke incidences are

projected to grow from 1.1M per year in

2000 to >1.5M per year in 2025.4

Across the European Union the total

cost of stroke was estimated to exceed

27€B.8

The cost to treat stroke is projected to

double from $72B in 2010 to $183B in

2030.9

Nearly 7.4M stroke survivors in the US

and Canada are experiencing a lifelong

recovery process.2, 3

Globally between 250,000 and

500,000 people suffer an SCI

annually.5

People with SCI are two to five

times more likely to die

prematurely.5

250,000 Americans are living with SCI

and 17,500 new cases per year6

The average LOS for SCI in acute care

is 15 days and in rehabilitation 44 days

totaling $198,000.6

In Europe, approximately 333,000

people are living with SCI.7

In Europe, there are about 11,000

new cases per year attributed to

vehicular or sports accidents

alone.7

Current Treatment Options

Current “technologies” are sub-optimal

o Labor-intensive for PTs

o Limited high dose/high intensity therapy

o Do not support early mobilization

o Limited patient engagement

o Do not restore a normal gait pattern

o 15 minutes = average time stroke inpatients currently spend on

mobility tasks PER DAY

o A severe stroke inpatient spends an average of ~95.5% of the

day in bed

Today there is no consistent standard of care


Significant Unmet Need

Fastest patient to patient change-overWearable Exoskeleton

Promotes early mobility and corrects posture

Hand-Held Controller

Real-time adjustments by physical therapists

Adjustable Software

Enables personalization for unique challenges

SmartAssist Software

Prepares a patient to get back on their feet

EksoPulse Analytics

Quantifiable utilization metrics in the cloud


Only FDA Cleared Exoskeleton for Stroke & SCI


C1

C2

C3

C4

C5

C6

C7

C8

T1

T2

T3

T4

T5

T6

T7

T8

T9

T…

T…

T…

L1

L2

L3

L4

L5

S1

S2

S3

S4

S5

Discharge rate

by injury level

Wide SCI range

Hemiplegia

Continuum of care

(*) See website for label

Addressing Broadest Array of Patient Need

quick-fit Stand/Sit PreGait SmartAssist Free Gait beyond

Remembers

patients from

session to

session

New options offer

comfort for larger

patients

Supported squats,

balance, and

marching help build

strength to start

walking

More intuitive

forces to help

patients learn

step through

Stance assist to

help patients to

gain stance

strength

Gravity-supported

walking for high

step dosage

FES interface for

next-generation

therapy

Broad-based applicability – both by disease state and throughout patient stay - enables hospitals to

enhance ROI


Improving Outcomes and Cost of Care

Administrator

“Skeptic”

Patient &

Caregivers

“Friend”

Pa

tie

nt C

ap

ab

ility

(FIM

sco

re, D

ista

nce

, B

ala

nce

, G

ait)

t = 0Average Length of Stay

(Days)

Current SOC: 2-3 PTs for acute

stroke manual therapy with risk

of readmission after discharge1

Goal: 1-2 PTs for acute stroke

robotic therapy with reduced risk

of readmission yet same length

of stay. *

(*) Actuals under clinical evaluation

Powered exoskeletons could increase early mobility improve function and reduce cost of care

Increased motor FIM scores1

Increased distances walked1

Improved balance2

Established a more natural gait3

Increased aerobic endurance, leg strength4

Promoted Neuroplasticirty5

Better Patient Outcomes

9Ekso Bionics | 9© 2018 Ekso Bionics Holdings, Inc. All Rights Reserved.

Empowering Customers to Achieve Excellence

Hospital: Rehabilitation with Ekso GT Reduces Costly Co-Morbidities

Rehab Facility: Increased Revenue and Cost Efficiencies

Early Mobilization reduces risk of complications6

Walking reduces incidences of UTI, DVT, HAP7, 8, 9

Walking leads to better discharge outcome1

Attraction of more (profitable) patients/expansion of catchment area for facility

Increased billable sessions per day

Reduction in labor costs

Possible reduction in PT injuries/turnover

Feasibility, single case

or case series,

comparative & single

arm multicenter


Completed

29 Studies

o 8 SCI

o 4 stroke

o 2 multi-injury

N = ~400 patients

Ongoing

17 Studies

o 7 SCI

o 4 stroke

o 1 MS, 1CP

N = ~600 patients

Wise study

(Ekso-sponsored,

8+ centers)

Upcoming

Registry – HTA Type (RIC coordinating site)

Stroke Rehab (Kessler Foundation, Karen Nolan(1))

o Examining impact on gait function, balance, and

neuromuscular responses, as well as community

participation and overall quality of life.

Stroke, EMG, EEG – Neuro-gait project goals (EMEA)

o Developing hardware and integrate EMG/EEG data for

bio-signal processing with Ekso

o Indexing prognosis for motor recovery after stroke

SCI (Alberta Health Services; grant-funded)

o Seven Ekso sites matched with seven non-Ekso sites

o Six and 12 week training with durability assessments

SCI and Reduction in Bone Loss – Sheffield Project

SCI – EKSO, pharma, stimulation

o Determine effects of non-invasive electrical and

pharmacological neuromodulation on standing and

stepping in Ekso.

o Develop closed-loop EMG biofeedback system that

adjusts robot

Clinical Evidence Roadmap

Multi-center, larger

sample sizes in some

studies

(1) See http://www.eurekalert.org/pub_releases/2016-01/kf-kfa010716.php

(2) See March 2017 Clinical Summary on website

Research has shown training in Ekso GT is safe and

progression in the device is feasible. Early data

demonstrates training improves walking and functional

outcomes.(2)

http://www.eurekalert.org/pub_releases/2016-01/kf-kfa010716.php

Early Adopters Pave Way for Broad UtilizationEarly Adopters Pave Way for Broad Utilization

© 2018 Ekso Bionics Holdings, Inc. All Rights Reserved. Ekso Bionics | 11

Ekso GT Outpatient Case Study


Shifted rehabilitation program to focus on Neuroplasticity

o Repetition, practice fundamentals

o Task specificity and intensity

o Normal biomechanics with minimal compensation

Within 3-months, Ekso GT was in usage 35+ hours/week

Staff sees better outcomes and patients improving more

quickly

Within 12-months, success in the out-patient setting led to

purchase of a 2nd Ekso GT for use in-patient

Transitioned from 2 PTs to 1 PT

Expanded catchment area from a 20-mile range to six hours

and a 110% increase in locomotor training

The number of patients who used the Ekso GT during in-patient rehabilitation who required

robotic gait training when they entered the outpatient setting was reduced by 50%

Capital investment $150,000

5-Year EBITDA $513,000

Payback Period <2 years

IRR >50%

5-Year Financial Return(1)

(1) From December 2016 presentation at Ekso Bionics’ Analyst Technology Day

Direct

Distributor

Global Headquarters:

Richmond, CAEMEA Headquarters:

Germany

North America

• 5 Direct Sales People

• 6 Clinical Specialists

• National AccountEMEA

• 3 Direct Sales People

• 4 Clinical Specialists

• Distributors Manager

Focus on key in- and out-patient

centers that provide stroke and SCI

rehabilitation

Sales and support currently consist of

35+ professionals

A typical Ekso package includes:

o an Ekso GT

o two sets of batteries for continuous run-time

o training through two levels of certification

o SmartAssist software

o Ekso Care - 1- to 4-year after-sales service

Sales cycle currently averages 12

months


Sales Overview

Gait training post-stroke

SCI up to C-7 (ASIA D)

Suit adjusts to fit patient (<10 minutes)

Software adjustable while walking

One size fits most patients

Multiple indications with one device

Home use

Ekso

Strong Competitive Position

ReWalk Indego

IndegoReWalk

Non FDA-cleared medical

exoskeleton companies:

Cyberdyne (Japan)

Bionik Labs (Canada)

Rex Bionics (NZ/UK)


Building a Trusted Brand to Serve Growing Mobility Challenges

Minor

Moderate

Major

18,980,000 (1)

Moderate: persons reporting a lot of

difficulty with walking or climbing

stairs or standing or uses a walker

Minor: persons reporting some difficulty

with walking or climbing

stairs or standing or uses a

cane/crutches

Major: persons reporting being unable to

perform walking or climbing

stairs or standing or uses a manual or

powered wheelchair or scooter

(1) Lezzoni L et al, Mobility Difficulties Are Not Just a Problem of Old Age; Journal General Internal Medicine, Volume 16, Issue 4, pages 235–243, April 2001; N=145,000

30%

28%

42%

Potential

addressable

home

mobility

market

(US Only)

Adaptable to most

surfaces and slopes

Increased independence

More affordable

(reimbursement)

Versions of products

available to support

different levels of need

Requirements to meet

needs for home mobility


Home Mobility- Products for Different Disease States

A Strategy for Success


Own the rehabilitation market

o Best in class technology, key opinion leaders, multi-unit centers

Establish Ekso as standard of care

o Clinical studies providing data for early identified potential outcomes

o Support customer revenue growth and cost savings

Enable rehabilitation to serve as “Base Camp” for broader

business

o Platform for safety, efficacy and cost effective technology

Develop home mobility and wellness product$20+B Addressable Market (US only)

Home/community mobility

Chronic conditions: SCI, Stroke, TBI

Endurance impaired conditions:

oOsteoarthritis

oMultiple Sclerosis

oParkinson’s Disease

oCerebral Palsy

$1+ B Global Addressable Market

Rehabilitation facilities

Acute conditions:o SCI

o Stroke

Basecamp

Light weight

Strength augmentation

Natural range of motion

Load carriage (load bearing)

Ultra Low Power Consumption

Geometries for tool holding/load lifting

Novel Actuation strategies

Enhanced endurance

Safe and effective

Energy efficiency

Medical

Energy efficient

Load carriage

Un-actuated

exoskeleton structure

Control methods for

assisting gait

Efficient hydraulic

actuation

Methods on how medical

exoskeleton decides when to

initiate gait

Basic exoskeleton IP for

variable assist

Add-ons that complement

exoskeleton usability

Able Bodied

65 U.S. Patents

28 issued

33 in prosecution

3 provisional

214 Int’l Patents

112 issued

102 in prosecution


Industry Leading, Extensive IP Portfolio

Ekso Works Mount Products

Makes tools weightless (up to 36lbs)

Works with existing tools and existing work platforms

Minimal Training Required (<5 min)

Increases Safety

Increases Productivity

Increases Quality

Reduces Fatigue

“Now one man operates safely and

precisely. They use half the manpower

and currently are producing nearly twice

the output in the same time.”

- Neil Young, VCC


Able-bodied Industrial Solutions

Human Capability Augmented with Mechanical Strength and Endurance

• Offloads heavy tool weights

• Ease of adoption

• Works with existing tool and work

platforms

• Makes arms buoyant

• Provides increased agility / lower

direct tool weight on worker

• Facilitates Chest Level and

Overhead Tasks

• Offloads heavy tool weights

• Enhances worker mobility &

endurance

H2/2016 H2/2017 2018

Ekso Zero G Ekso Vest Ekso Suit


Sofor Commercial Success

Trusted brand with commercial traction

Transitioning to Standard of Care to tap $1+ billion market opportunity, with

potential to expand

o Applications and target customer

o Geographic footprint to Asia

Investing further in product development for next generation suite of home

mobility and wellness products

Building Ekso Works

o Arms, vests and suits

o Leverage IP for additional financial upside

Solid Cornerstones for Commercial Success

Ekso Bionics |22© 2018 Ekso Bionics Holdings, Inc. All Rights Reserved.

Thank You

“Movement is the

essence of life”- Bernd Heinrich


Unique Insight for Rehabilitation

1. Russo A et al, Utilization of a robotic exoskeleton to provide increased mass practice for gait training and its impact on discharge destination for individuals with

acute stroke. Poster presented at International Stroke Conference, 2016.

2. Arun Jayaraman, PT, PhD, et al, Evaluation of the Clinical Criteria for Safe and Efficient Use of Exoskeletons in Individuals with SCI, presented at of the at the

2013 American Spinal Injury Association (ASIA) conference, 2013

3. Salbach NM, et al, A task-orientated intervention enhances walking distance and speed in the first year post stroke: a randomized controlled trial , Clin Rehabil

May 2004; vol. 18 no. 5, 509-519.

4. Knorr S, et al, Perspective on neuromuscular factors in post-stroke fatigue, Disabil Rehabil. 2012;34(26):2291-9. doi: 10.3109/09638288.2012.683233. Epub

2012 Jun 5.

5. Good Shepherd case study

6. Cumming T et al, Very Early Mobilization After Stroke Fast-Tracks Return to Walking, Further Results From the Phase II AVERT Randomized Controlled Trial;

Stroke, 2011; 42: 153-158.

7. Rogers MAM et al, Mobility and other predictors of hospitalization for urinary tract infection: a retrospective cohort study, BMC Geriatrics2008, 8:31.

8. Bravata DM et al, Processes of care associated with acute stroke outcomes, Arch Intern Med. 2010 May 10;170(9):804-10.

9. Pashikanti L et al, Impact of Early Mobilization Protocol on the Medical-Surgical Inpatient Population: An Integrated Review of Literature, Clinical Nurse

Specialist: March/April 2012 - Volume 26 - Issue 2 - p 87–94.


Sources

ekso sko17 moving as one - content.equisolve.netoverview_jan+2018+u… · fes interface for...

Documents